JULY 1-2, 2021
Agenda
Displaying agenda in the event’s time zone (CET, GMT +2)
Pre-Conference Masterclass: Best Practices to Create / Write Effective and Impactful CI Reports and Presentations
An “art” and “science” exists when considering clear, concise and actionable competitive strategy report writing in the biopharmaceutical space.
Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.
Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.
In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.
This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.
Presented by Molekule Consulting
Chairpersons’ Opening Remarks
Keynote: How to Build a Successful and Sustainable CI Function
Daniel will share with the audience his learnings and experiences in building and leading successfully several CI teams over a time span of more than 20 years in the industry.
Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them
The audience can expect to be able to participate actively in the “conversation” and contribute to the program
Presented by Molekule Consulting
Keynote: Late Life Cycle Management (LLCM): The Strategic Value of Generic & Biosimilar CI In Life Sciences
This session will provide insights and highlight best practices to enable LLCM value and asset maximization by leveraging a number of tools unique to CI professionals. Specifically this presentation will enable you to:
* Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
* Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
* Understand Gx / biosimilar product development and entry strategies
* Identify potential actions to optimize launches
Presented by INOVIS
VIRTUAL EXHIBITION HALL/LIVE DEMOS/LIVE STREAMS
VIRTUAL EXHIBITION HALL/ONE ON ONE MEETINGS/LUNCH
SESSION ONE
When CI goes Global: a 10 Year Journey to Bring Intelligence at Global Level
Presented by Chiesi Farmaceutici S.p.A.
SESSION TWO
Adapting Predictive Analytics in an Organization to Gain Competitive Edge
Presented by Lonza
SESSION ONE
The Forgotten Pharma CI Corner; Cost of Goods (COGs) Intelligence
With the CAR-T and gene therapy revolutions, biosimilar /biobetter challenges to long established biologic innovators and a surge in vaccine innovation, manufacturing and supply chain intelligence is rising in its importance.
In 2014 Dig Worldwide developed and introduced COGIntel a quick, robust and cost effective COGs benchmarking solution.
Technical Cost Modelling (TCM) , a method developed at MIT in the 1980’s has long been the gold standard in benchmarking cost-of-goods sold which is time and resource intensive with a limited shelf-life. Although not as precise as TCM, Dig Worldwide’s bespoke COGIntel method allows rapid and cost effective COG benchmarking analysis that provides “good enough” competitive intelligence for strategic decision making. Performance gaps and areas of advantage or disadvantage become visible verses forgotten.
An illustrative CAR-T case study will form an integral part of the talk to help illustrate Dig Worldwide’s methodology.
Presented by Dig Worldwide
SESSION TWO
Managing Future Competitive Risk in R&D: An ML Based Approach to Understand the Drivers of Success & Failure
Helping pharma companies understand competitive risk in R&D using Product Specific Probability of Approval (PTRS). Learnings taken from utilising unbiased and transparent Machine Learning approach in understanding drug success and failure drivers.
Presented by Evaluate
VIRTUAL EXHIBITION HALL/LIVE DEMOS/LIVE STREAMS
SESSION ONE
10 Lessons from a CI Life
Marjorie Norman has seen a lot of changes over the past 25 years as a CI professional in both industry and consultancy. However, some basic truths still hold strong. This session will address Marjorie’s experience - the good, the bad and the ugly - in developing and maintaining a best-in-class CI program.
Presented by Cambridge Healthcare Research
SESSION TWO
TBA
SESSION ONE
How to Measure Impact on your Organization
Presented by Galderma
SESSION TWO
Business Case – When to Prepare It, What Shall Be In, What Is the Impact of CI and MR on Business Case Outcome and How to Communicate It to Decision Makers
Presented by Tillotts Pharma
NETWORKING ROUNDTABLES
ROUNDTABLE 1
More Effectively Collaborate With Your Colleagues and Agencies to Drive Enhanced CI and Business Planning at Your Company
Presented by Bayer
ROUNDTABLE 2
Artificial Intelligence
Presented by Sanofi
One-On-One Meetings
Pre-Conference Masterclass: Developing a Competitive Activity Framework to Enhance Organizational Competitiveness
This workshop session (with breakouts), will give participants first-hand insights from a combined 30+ years of experience in delivering strategic and tactical workshop-style solutions, using an optimal blend of established CI frameworks alongside INOVIS’ in-house proprietary methodologies.
Key to this session will be addressing business needs across the lifecycle, whereby participants will:
* Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
* Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
* Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.
Presented by INOVIS
Welcome and Re-Cap of Day One
Keynote: Megatrends in Healthcare
This talk will discuss the interplay of various factors that are currently influencing the healthcare and pharmaceutical landscapes and the emerging trends that are shaping the new era of healthcare.
How can we use demographic shifts to help inform new business models? How will digital disruption affect drug development and access? How are mHealth platforms shifting patients’ approaches to healthcare?
Presented by Lifescience Dynamics
Keynote: Lessons From Inside Novartis, Roche, and Atacana – 5 Questions You Need to Ask to Maximize Your Success and Significantly Increase the Value of Your Competitive Intelligence
Many CI professionals fail to understand that the perceived value of their CI work is the basis for their career success. Still, others fail to realize that they must translate the importance of their insights into long-term gains for the stakeholders in the stakeholders' perception.
One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:
1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion
In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.
Presented by Atacana Group
VIRTUAL EXHIBITION HALL/LIVE DEMOS/LIVE STREAMS
VIRTUAL EXHIBITION HALL/ONE ON ONE MEETINGS/LUNCH
SESSION ONE
How to Best Track Generics Entering the Market
Presented by Janssen
SESSION TWO
Designing Winning Trials for Reimbursement - Strategic Framework
- Learn HTA reimbursement approval/rejection rates
– Reflect On Key Strategic Elements when designing Ph III
– Tradeoffs between HTA requirements and Clinical Developing Plans
– Main tactics at hand for clinical trial design
Presented by Novartis
SESSION ONE
How to Use Purchase Decision Maker Insights to Drive Strategic Decisions
Key purchase decision makers of Life science (LS) products are generally have different buying decision criteria than the actual end users. This creates a disconnect between the LS product value proposition of the key decision maker and that of the end user.
A result of this can be dissatisfied end users and low utilization rates. Understanding the value proposition disconnect and developing strategies to better align the two value propositions can improve both patient and sales outcomes.
This session will describe how Win/Loss for the LS market can generate new insights into intermediate and end user decision factors and demonstrate how to adjust the value proposition to improve the match for both end user and purchase decision maker. With a particular emphasis on drug formulary, delivery systems, surgical devices, and medical imaging products, the session will discuss how to design a Win/Loss program for LS, how to interpret Win/Loss findings for strategy development, and how a Win/Loss program of LS differs from typical Win/Loss programs.
Session attendees will gain a deeper understanding of how Win/Loss can apply to LS and drive strategy. Real world (blinded) examples of Win/Loss components (questionnaires, interview excerpts, and analysis reports) will be presented to illustrate the different tools and benefits of a Win/Loss program.
Presented by Fletcher/CSI
SESSION TWO
Emerging Trends within the Biopharma Industry: The Evolution of Challenges and Rising Opportunities
Are there untapped opportunities within the biopharma industry? Prescient has noticed a high volume of changes and vast opportunities for success in developing markets and technologies.
If biopharma companies want to expand in these emerging areas, their strategy must be tailored to the developing pace of change. We will discuss the most promising emerging areas, to lay out the opportunities, challenges and trends that will drive change and explain how CI can help steer organizational strategic success.
Presented by Prescient Healthcare Group
VIRTUAL EXHIBITION HALL/LIVE DEMOS/LIVE STREAMS
SESSION ONE
What Winners Do - Cracking the Code of Sales Force Deployment in Medical Devices
Presented by Johnson & Johnson
SESSION TWO
TBD
Presented by Vifor Pharma
Networking Roundtables
ROUNDTABLE 1
Beyond “Usual” Intelligence on Medicinal Products: How to Monitor Digital Scenario
Presented by Chiesi Farmaceutici S.p.A.
ROUNDTABLE 2
Personal Professional Challenges – How to Sell your Analysis Internally
Presented by SOTIO, a.s.